Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“July is Sarcoma Awareness Month – it’s a time to shine a light on sarcomas and all rare cancers.
I spoke with TV News Channel 5 about why early detection matters and how clinical trials offer hope for those facing limited options
– Rare doesn’t mean invisible. And awareness is more than a campaign, it’s a call to action
– Every early diagnosis, every trial, every voice, it all matters.”
Watch the video attached to this post.
More posts featuring Vivek Subbiah on OncoDaily.